Video

Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research

Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.

Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.

Transcript (slightly modified)

Can you describe the transition in diabetes research from focusing on glycemic results to costs for health systems?

Over the last year or so we’ve made a concerted effort to switch our evidence strategy from that of solely glycemic control to one of the hard outcomes. We call the glucose control more of an intermediary outcome and we know that we can reduce hypoglycemia in hospitals. We know that we can reduce hypoglycemia and keep people in that glucose target range more frequently.

Now what we want to do, and what we have done, is proven that improving that intermediate outcome actually improves the harder outcomes. The hard outcomes to me, especially as a clinician, are length of stay so my patients can go home sooner from the hospital, readmissions so my patients don’t have to come back in the hospital, obviously both of those are advantageous, but we can also reduce infection rates etc. So, that’s what we have targeting here over the last little bit, making sure that glucose control translates into those harder outcomes and the financial outcomes that they reward as well.

Related Videos
Drs Lillian L. Siu and Matthew G. Vander Heiden
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo